Biocartis Group NV (BCART) - Total Liabilities

Latest as of June 2023: €166.97 Million EUR ≈ $195.20 Million USD

Based on the latest financial reports, Biocartis Group NV (BCART) has total liabilities worth €166.97 Million EUR (≈ $195.20 Million USD) as of June 2023. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Biocartis Group NV to track the company's year-over-year net asset growth rate.

Biocartis Group NV - Total Liabilities Trend (2012–2022)

This chart illustrates how Biocartis Group NV's total liabilities have evolved over time, based on quarterly financial data.

Biocartis Group NV Competitors by Total Liabilities

The table below lists competitors of Biocartis Group NV ranked by their total liabilities.

Company Country Total Liabilities
Pato Chemical Industry Public Company Limited
BK:PATO
Thailand ฿75.17 Million
Pelayaran Nelly Dwi Putri Tbk
JK:NELY
Indonesia Rp326.66 Billion
ANAX Metals Ltd
AU:ANX
Australia AU$22.55 Million
Daechang Steel Co Ltd
KQ:140520
Korea ₩135.24 Billion
MDI Energia S.A.
WAR:MDI
Poland zł87.24 Million
Perusahaan Sadur Timah Malaysia Perstima Bhd
KLSE:5436
Malaysia RM493.74 Million
Bubang Co. Ltd
KQ:014470
Korea ₩81.19 Billion
Woosung Feed
KO:006980
Korea ₩253.24 Billion

Liability Composition Analysis (2012–2022)

This chart breaks down Biocartis Group NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BCART company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.15 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -3.09 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.48 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Biocartis Group NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Biocartis Group NV (2012–2022)

The table below shows the annual total liabilities of Biocartis Group NV from 2012 to 2022.

Year Total Liabilities Change
2022-12-31 €144.56 Million
≈ $169.01 Million
-18.04%
2021-12-31 €176.38 Million
≈ $206.20 Million
+1.55%
2020-12-31 €173.69 Million
≈ $203.07 Million
-5.52%
2019-12-31 €183.84 Million
≈ $214.93 Million
+253.32%
2018-12-31 €52.03 Million
≈ $60.83 Million
+6.30%
2017-12-31 €48.95 Million
≈ $57.23 Million
+10.21%
2016-12-31 €44.42 Million
≈ $51.93 Million
+32.74%
2015-12-31 €33.46 Million
≈ $39.12 Million
+2.23%
2014-12-31 €32.73 Million
≈ $38.27 Million
+16.11%
2013-12-31 €28.19 Million
≈ $32.96 Million
-4.08%
2012-12-31 €29.39 Million
≈ $34.36 Million
--

About Biocartis Group NV

BR:BCART Belgium Diagnostics & Research
Market Cap
$31.84 Million
€27.24 Million EUR
Market Cap Rank
#24028 Global
#96 in Belgium
Share Price
€0.29
Change (1 day)
+0.00%
52-Week Range
€0.29 - €0.29
All Time High
€12.88
About

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progres… Read more